title: Establishment of the first WHO international genetic reference panel for Prader Willi and Angelman syndromes.
abstract: Prader Willi and Angelman syndromes are clinically distinct genetic disorders both mapping to chromosome region 15q11-q13, which are caused by a loss of function of paternally or maternally inherited genes in the region, respectively. With clinical diagnosis often being difficult, particularly in infancy, confirmatory genetic diagnosis is essential to enable clinical intervention. However, the latter is challenged by the complex genetics behind both disorders and the unmet need for characterised reference materials to aid accurate molecular diagnosis. With this in mind, a panel of six genotyping reference materials for Prader Willi and Angelman syndromes was developed, which should be stable for many years and available to all diagnostic laboratories. The panel comprises three Prader Willi syndrome materials (two with different paternal deletions, and one with maternal uniparental disomy (UPD)) and three Angelman syndrome materials (one with a maternal deletion, one with paternal UPD or an epigenetic imprinting centre defect, and one with a UBE3A point mutation). Genomic DNA was bulk-extracted from Epstein-Barr virus-transformed lymphoblastoid cell lines established from consenting patients, and freeze-dried as aliquots in glass ampoules. In total, 37 laboratories from 26 countries participated in a collaborative study to assess the suitability of the panel. Participants evaluated the blinded, triplicate materials using their routine diagnostic methods against in-house controls or externally sourced uncertified reference materials. The panel was established by the Expert Committee on Biological Standardization of the World Health Organization as the first International Genetic Reference Panel for Prader Willi and Angelman syndromes.
authors.affiliation: National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Herts, UK. Jennifer.Boyle@nibsc.hpa.org.uk
authors.forename: Jennifer
authors.initials: J
authors.lastname: Boyle
authors.forename: Malcolm
authors.initials: M
authors.lastname: Hawkins
authors.forename: David E
authors.initials: DE
authors.lastname: Barton
authors.forename: Karen
authors.initials: K
authors.lastname: Meaney
authors.forename: Miriam
authors.initials: M
authors.lastname: Guitart
authors.forename: Anna
authors.initials: A
authors.lastname: O'Grady
authors.forename: Simon
authors.initials: S
authors.lastname: Tobi
authors.forename: Simon C
authors.initials: SC
authors.lastname: Ramsden
authors.forename: Rob
authors.initials: R
authors.lastname: Elles
authors.forename: Elaine
authors.initials: E
authors.lastname: Gray
authors.forename: Paul
authors.initials: P
authors.lastname: Metcalfe
authors.forename: J Ross
authors.initials: JR
authors.lastname: Hawkins
mesh_terms: D017204:Angelman Syndrome / Q000175:diagnosis* / Q000235:genetics*; D002461:Cell Line, Transformed; D005260:Female; D006801:Humans; D008297:Male; D025202:Molecular Diagnostic Techniques / Q000592:standards*; D011218:Prader-Willi Syndrome / Q000175:diagnosis* / Q000235:genetics*; D044767:Ubiquitin-Protein Ligases / Q000235:genetics; D014944:World Health Organization
chemical_list: C471639:UBE3A protein, human; D044767:Ubiquitin-Protein Ligases